Tumor Specific cfDNA Predicts Treatment Response of Multiple
Myeloma Patients

a 2018

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

VRÁBEL, Dávid; Jana GREGOROVÁ; Lenka SEDLAŘÍKOVÁ; Martina ALMÁŠI; Renata BEZDĚKOVÁ et. al.

Basic information

Original name

Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients

Authors

VRÁBEL, Dávid (703 Slovakia, belonging to the institution); Jana GREGOROVÁ (203 Czech Republic, belonging to the institution); Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution); Martina ALMÁŠI (203 Czech Republic); Renata BEZDĚKOVÁ (203 Czech Republic); Martin ŠTORK (203 Czech Republic); Marta KREJČÍ (203 Czech Republic); Zdeněk ADAM (203 Czech Republic); Luděk POUR (203 Czech Republic); Roman HAJEK (203 Czech Republic) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution)

Edition

60th Annual Meeting of the American-Society-of-Hematology (ASH), 2018

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 16.601

RIV identification code

RIV/00216224:14110/18:00120122

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1182/blood-2018-99-114793

UT WoS

000454842801007

Keywords in English

cell-free dna; multiple myeloma; neoplasms; immunoglobulin heavy chains; polymerase chain reaction; liquid biopsy; massively-parallel genome sequencing; molecule; biopsy; bone marrow specimen

Abstract

In the original language

Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous cancer of plasma cells characterized by multiple focal lesions in the bone marrow (BM). Hence, a single-site biopsy can create a sampling bias. In spite of this, BM samples are typically used for MRD analysis, but currently an alternative approach called liquid biopsies, which utilizes body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA (cfDNA) as one type of the molecule which can be analyzed using liquid biopsy approach showed promising results previously. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in bone marrow samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.

Links

NV17-29343A, research and development project

Name: Analýza mikroprostředí kostní dřeně u extramedulárního relapsu mnohočetného myelomu

Cite

VRÁBEL, Dávid; Jana GREGOROVÁ; Lenka SEDLAŘÍKOVÁ; Martina ALMÁŠI; Renata BEZDĚKOVÁ; Martin ŠTORK; Marta KREJČÍ; Zdeněk ADAM; Luděk POUR; Roman HAJEK and Sabina ŠEVČÍKOVÁ. Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients. In 60th Annual Meeting of the American-Society-of-Hematology (ASH). 2018. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood-2018-99-114793.

@proceedings{1787324,
   author = {Vrábel, Dávid and Gregorová, Jana and Sedlaříková, Lenka and Almáši, Martina and Bezděková, Renata and Štork, Martin and Krejčí, Marta and Adam, Zdeněk and Pour, Luděk and Hajek, Roman and Ševčíková, Sabina},
   booktitle = {60th Annual Meeting of the American-Society-of-Hematology (ASH)},
   doi = {http://dx.doi.org/10.1182/blood-2018-99-114793},
   keywords = {cell-free dna; multiple myeloma; neoplasms; immunoglobulin heavy chains; polymerase chain reaction; liquid biopsy; massively-parallel genome sequencing; molecule; biopsy; bone marrow specimen},
   language = {eng},
   title = {Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients},
   url = {https://ashpublications.org/blood/article/132/Supplement%201/3188/263958/Tumor-Specific-cfDNA-Predicts-Treatment-Response},
   year = {2018}
}

TY  - CONF
ID  - 1787324
AU  - Vrábel, Dávid - Gregorová, Jana - Sedlaříková, Lenka - Almáši, Martina - Bezděková, Renata - Štork, Martin - Krejčí, Marta - Adam, Zdeněk - Pour, Luděk - Hajek, Roman - Ševčíková, Sabina
PY  - 2018
TI  - Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients
KW  - cell-free dna
KW  - multiple myeloma
KW  - neoplasms
KW  - immunoglobulin heavy chains
KW  - polymerase chain reaction
KW  - liquid biopsy
KW  - massively-parallel genome sequencing
KW  - molecule
KW  - biopsy
KW  - bone marrow specimen
UR  - https://ashpublications.org/blood/article/132/Supplement%201/3188/263958/Tumor-Specific-cfDNA-Predicts-Treatment-Response
N2  - Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous cancer of plasma cells characterized by multiple focal lesions in the bone marrow (BM). Hence, a single-site biopsy can create a sampling bias. In spite of this, BM samples are typically used for MRD analysis, but currently an alternative approach called liquid biopsies, which utilizes body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA (cfDNA) as one type of the molecule which can be analyzed using liquid biopsy approach showed promising results previously. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in bone marrow samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.
ER  -

VRÁBEL, Dávid; Jana GREGOROVÁ; Lenka SEDLAŘÍKOVÁ; Martina ALMÁŠI; Renata BEZDĚKOVÁ; Martin ŠTORK; Marta KREJČÍ; Zdeněk ADAM; Luděk POUR; Roman HAJEK and Sabina ŠEVČÍKOVÁ. Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients. In \textit{60th Annual Meeting of the American-Society-of-Hematology (ASH)}. 2018. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood-2018-99-114793.

Přehled o publikaci